Information Provided By:
Fly News Breaks for January 9, 2020
FATE
Jan 9, 2020 | 05:17 EDT
BMO Capital analyst Do Kim downgraded Fate Therapeutics to Market Perform from Outperform with an unchanged price target of $22. The "clean" iPSC safety and positive FT516 efficacy expectations are fully reflected in the shares, Kim tells investors in a research note. The analyst sees greater downside risk to 2020 clinical updates and views the Fate's IPSC opportunity as fairly valued.
News For FATE From the Last 2 Days
There are no results for your query FATE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.